Dr. Mildred R. Ridgway, MD

Dr. Ridgway practices at University of Mississippi Medical Center in Jackson, Mississippi, part of Mississippi Institutions of Higher Learning.

Dr. Ridgway's NPI, 1134111867, was assigned on August 18, 2005. Dr. Ridgway graduated from Tulane University School of Medicine in 1998. Dr. Ridgway holds Mississippi license 18985.

Dr. Ridgway's primary practice is University of Mississippi Medical Center, at 2500 N State St, Jackson, MS 39216 in Hinds County. The practice phone is (601) 984-4100.

Dr. Ridgway's primary practice is University of Mississippi Medical Center in Jackson, Mississippi, part of Mississippi Institutions of Higher Learning. The medical group on file is University of Mississippi Medical Center. Dmand AI also links Dr. Ridgway to 2 more group practices and clinics, 1 behavioral health center and 1 medical group, each named with a free account. Dr. Ridgway's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ridgway practices, 4 sites in all. Vendor and product names are available with a free account.

Gynecologic oncology is Dr. Ridgway's primary specialty in the NPI Registry, under taxonomy code 207VX0201X. Dr. Ridgway is licensed in Mississippi.

CMS data shows 239 Medicare services from Dr. Ridgway across 5 procedure codes in 2024, for 167 Medicare patients. Medicare paid $25,195 for them.

CMS counts 167 Medicare patients who saw Dr. Ridgway in 2024. The largest group is 65 to 74, with 85 patients. 73% of them have high blood pressure, and 62% have high cholesterol. 24% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ridgway's median patient age at 57, with 99% women.

In 2024, Dr. Ridgway wrote 136 Medicare Part D claims for 58 patients. 69% of them were for generic drugs. CMS names the drug for 48 of them, across 3 drugs with 11 or more claims each, at $926 in total drug cost. In 2023, CMS named 50 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Ridgway for performance year 2024, reported as part of a group. Dr. Ridgway accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 11 procedures of removal of the uterus by Dr. Ridgway, more than 85% of the clinicians it reports for that procedure.

Dmand AI links 13 papers to Dr. Ridgway, published from 2014 to 2023. 2021 was the busiest year, with 3. The most frequent topics are Ovarian Neoplasms, Pregnancy, Abdominal and Tomography, X-Ray Computed. Dr. Ridgway has published most often in Am Surg. Dr. Ridgway's most frequent co-authors are Srinivasan Vijayakumar, MD, Toms Vengaloor Thomas, MD and Anu Elizabeth Abraham, MD.

Dmand AI links Dr. Ridgway to 5 clinical trials. 4 are still active or recruiting. Conditions studied include Carcinoma, Endometrioid, Fallopian Tube Diseases and Lymphedema. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 172 general payments to Dr. Ridgway from 26 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 50% of the total. Merck Sharp & Dohme Corporation paid the most, $30,355.

Dr. Ridgway graduated from Tulane University School of Medicine in 1998.